Exact Sciences (EXAS) Competitors $52.82 -1.05 (-1.94%) Closing price 07/3/2025 03:12 PM EasternExtended Trading$52.82 0.00 (0.00%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, RGEN, MDGL, HALO, and IONSShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Exact Sciences (NASDAQ:EXAS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment. Is EXAS or BIIB more profitable? Biogen has a net margin of 15.07% compared to Exact Sciences' net margin of -36.06%. Biogen's return on equity of 14.03% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-36.06% -3.75% -1.68% Biogen 15.07%14.03%8.32% Does the media refer more to EXAS or BIIB? In the previous week, Biogen had 5 more articles in the media than Exact Sciences. MarketBeat recorded 20 mentions for Biogen and 15 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.16 beat Biogen's score of 0.95 indicating that Exact Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 11 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, EXAS or BIIB? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.76B3.61-$1.03B-$5.51-9.59Biogen$9.68B2.01$1.63B$10.1313.09 Which has more volatility and risk, EXAS or BIIB? Exact Sciences has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Do institutionals and insiders have more ownership in EXAS or BIIB? 88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 1.2% of Exact Sciences shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer EXAS or BIIB? Exact Sciences currently has a consensus target price of $70.40, indicating a potential upside of 33.30%. Biogen has a consensus target price of $188.48, indicating a potential upside of 42.12%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Exact Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38 SummaryBiogen beats Exact Sciences on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.07B$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-9.5921.4227.5020.21Price / Sales3.61281.76421.02118.64Price / Cash9.4842.7336.8958.07Price / Book4.077.518.045.67Net Income-$1.03B-$55.05M$3.18B$249.13M7 Day Performance-1.56%4.61%2.82%3.30%1 Month Performance-4.27%4.89%3.70%5.20%1 Year Performance22.29%5.84%35.41%21.38% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.9216 of 5 stars$52.82-1.9%$70.40+33.3%+22.3%$10.07B$2.76B-9.597,000Positive NewsAnalyst RevisionBIIBBiogen4.9334 of 5 stars$125.59-0.4%$188.48+50.1%-41.0%$18.40B$9.68B12.407,605INCYIncyte4.3408 of 5 stars$68.10-0.4%$74.53+9.4%+18.7%$13.18B$4.24B212.822,617UTHRUnited Therapeutics4.9955 of 5 stars$287.35+1.1%$386.15+34.4%-5.3%$12.96B$2.88B11.471,305Positive NewsNBIXNeurocrine Biosciences4.9201 of 5 stars$125.69+0.2%$162.00+28.9%-7.4%$12.44B$2.36B42.611,800Positive NewsEXELExelixis4.7408 of 5 stars$44.08+0.9%$43.56-1.2%+109.1%$12.02B$2.17B20.041,147Trending NewsAnalyst RevisionBMRNBioMarin Pharmaceutical4.9449 of 5 stars$54.97-0.4%$93.45+70.0%-29.3%$10.54B$2.85B20.443,040Analyst ForecastRGENRepligen4.813 of 5 stars$124.38+0.7%$172.83+39.0%+5.5%$6.99B$634.44M-276.401,778MDGLMadrigal Pharmaceuticals4.1045 of 5 stars$302.64+0.6%$420.63+39.0%+9.9%$6.72B$317.38M-16.7790HALOHalozyme Therapeutics4.852 of 5 stars$52.02-0.4%$61.90+19.0%+3.9%$6.41B$1.02B13.84390High Trading VolumeIONSIonis Pharmaceuticals4.6637 of 5 stars$39.51-0.7%$57.88+46.5%-5.7%$6.29B$705M-13.211,069Analyst Upgrade Related Companies and Tools Related Companies Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Repligen Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
